1 / 19

CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS

CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS. Stephen J. Gluckman, M.D. Botswana-UPENN Partnership. Microbiology. Encapsulated yeast 4 serotypes A ( C. neoformans v grubii ) B and C ( C. gatti ) D ( C. neoformans v neoformans ) All types can cause human disease Life cycle

harvey
Download Presentation

CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CRYPTOCOCCAL INFECTIONS IN PATIENTS WITH AIDS Stephen J. Gluckman, M.D. Botswana-UPENN Partnership

  2. Microbiology • Encapsulated yeast • 4 serotypes • A (C. neoformans v grubii) • B and C ( C. gatti) • D (C. neoformans v neoformans) • All types can cause human disease • Life cycle • Asexual: yeast that reproduce by budding • Human infections • Sexual: only seen in the laboratory

  3. Ecology and Epidemiology • World wide • C. neoformans associated with bird droppings • C. gatti not associated with birds, associated with eucalyptus trees • Generally an infection of immunocompromised but can cause clinical disease in healthy persons • Decreased Cell-mediated immunity • AIDS – CD 4 usually < 100 • Prolonged corticosteroids • Organ transplant

  4. Ecology and Epidemiology • 15-30% of AIDS patients in Sub-Saharan Africa* • Much less common in children • No person to person transmission *Powderly, WG Clin Infect Dis 1993

  5. Clinical Presentations • Pulmonary • Asymptomatic nodule • Symptomatic: not distinguishable from other causes • History, PE, routine laboratory testing does not produce features peculiarly suggestive of cryptococcal infection • Diagnosis • Staining of biopsy specimen • Culture of sputum and/or blood • Serum cryptococcal antigen (CRAG) • All patients with pulmonary disease need a CSF examination to r/o sub clinical meningitis

  6. Silver Stain

  7. Clinical Presentations • Cutaneous • Disseminated disease • Looks similar to molluscum contageosum • Diagnosis: • Unroofing a lesion and making a smear and culture • Serum CRAG • All patients with cutaneous disease need a CSF examination to r/o sub clinical meningitis

  8. Clinical Presentations • Cryptococcal Meningitis • Typical • Subacute onset of fever and headache • Photophobia and/or meningeal signs in only 25% • Less typical • Seizures • Confusion • Progressive dementia • Visual or hearing impairment • FUO • Diagnosis • CSF • Serum CRAG: > 99% sensitive in AIDS patients

  9. Cryptococcal Meningitis • In 2003 there were 193 (+) CSF cultures for cryptococcus from PMH * • Leucocytes • No leucocytes in 31% • Only 1-10 leucocytes in 23% • 7% had > 250 leucocytes • 30% of these had predominately PMN’s • 95% (+) India Ink • 1% (-) cryptococcal antigen • Literature • Sensitivity: 93-100% • Specificity: 93-98 % *Bisson et al

  10. India Ink

  11. Prognosis for Cryptococcal Meningitis • Prior to 1950 it was uniformly fatal • Amphotericin B introduced and mortality fell to the 30-40% range • In 1970’s 5-FC was released • Not for monotherapy • Decreased relapse rate when used with Amphotericin B • Mortality with current regimens: 10% • Predictors of death • Altered mental status • CSF CRAG > 1024 • CSF cell count < 20 • Changes in serum CRAG titer do not correlate with clinical outcome. So no need to follow

  12. Summary of Diagnostic Options • Culture • White mucoid colonies within 48hours • Blood cultures often (+) in immunosuppressed patients • 2/3rds with meningitis • Tissue • Silver or mucicarmine stain • India Ink for CSF • Cryptococcal antigen • Serum and CSF are 99% sensitive in AIDS patients • Serum is less sensitive in normal hosts

  13. Cryptococcal MeningitisTreatment • Antifungal agents • Induction • Consolidation • Maintenance • Pressure management

  14. Treatment**Modified IDSA Guidelines • Immunosuppressed (pulmonary, cutaneous, or meningitis) • Induction • Amphotericin B 0.7-1 mg/kg/day plus 5-flucytosine 100mg/kg/day x 2 weeks then • Consolidation • Fluconazole 400 mg/day x 6-10 weeks then • Suppression • Fluconazole 200 mg/day x ?

  15. Cryptococcal MeningitisTreatmentOne More Thing • Anti-fungal: induction, consolidation, maintenance • Pressure management • Elevated pressure • 75% > 200 • 25% > 350 • Repeated lumbar punctures • Increased pressure: daily until normal x several days • Normal pressure: recheck at 2 weeks prior to switching to fluconazole • Lumbar drain • VP shunt: if still elevated at 1 month • No role for • acetazolamide, mannitol • Steroids: ?

  16. Treatment • Other options • Fluconazole induction • Increased mortality • Not IDSA first choice • 5 FC monotherapy • Not an option because of resistance • 5-FC plus Fluconazole • Increased long term toxicity but an option • Caspofungin • No efficacy • Voriconazole • Good in vitro activity but little clinical experience

  17. Summary • Cryptococcal infections are common in patients with AIDS • In patients with AIDS cryptococcal infections are seen in patients with the lowest CD 4 (+) cell counts • Prolonged therapy and secondary prophylaxis is necessary • For meningitis both anti-fungal therapy and aggressive pressure management are required

More Related